Hikma boosts injectables business with Xellia assets acquisition
By Michele Maatouk
Date: Monday 17 Jun 2024
(Sharecast News) - Hikma Pharmaceuticals said on Monday that it has agreed to buy parts of Xellia Pharmaceuticals, a Copenhagen-based specialty company focusing on providing anti-infective treatments and other critical care therapies, for up to $185m.
Hikma will buy parts of Xellia's US finished dosage form (FDF) business and assets, including a commercial portfolio and pipeline of differentiated products, a manufacturing facility in Cleveland, Ohio, sales and marketing capabilities, and an R&D centre in Zagreb, Croatia.
The acquisition will add eight approved and marketed injectable products to Hikma's US portfolio and 11 pipeline products.
The Xellia commercial portfolio comprises the ready-to-use formulation, Vanco Ready® (vancomycin), launched in 2019, and other anti-infectives. These products are currently manufactured by a third-party and Hikma will maintain these manufacturing contracts while it upgrades the Cleveland facility, with the goal of moving production of these products in-house.
Chief executive Riad Mishlawi said: "Hikma has grown to become a top-three US supplier of sterile injectable medicines thanks to our strong record of successfully making value-enhancing acquisitions like this one.
"This acquisition will add significant scale to our US operations and will enhance our US injectable manufacturing capabilities and portfolio by adding complex technologies. I am confident that this transaction will deliver significant future value to our Injectables business, supporting growth over the medium term."
Hikma said its guidance for 2024 remains unchanged.
Email this article to a friend
or share it with one of these popular networks:
You are here: news
10 Lower Thames St,
London EC3R 6EN